Artemisinin-based combination therapy for ... - The Cochrane Library

2.2 Asia 1 317 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.16, 3.76]
2.3 Oceania 1 151 Risk Ratio (M-H, Fixed, 95% CI) 2.31 [0.85, 6.23]
3 Total Failure (P. falciparum) Day
28 PCR unadjusted
4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Africa 2 484 Risk Ratio (M-H, Fixed, 95% CI) 0.12 [0.05, 0.32]
3.2 Asia 1 451 Risk Ratio (M-H, Fixed, 95% CI) 0.43 [0.17, 1.12]
3.3 Oceania 1 224 Risk Ratio (M-H, Fixed, 95% CI) 1.27 [0.75, 2.15]
4 Total Failure (P. falciparum) Day
28 PCR adjusted
4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Africa 2 453 Risk Ratio (M-H, Fixed, 95% CI) 0.57 [0.17, 1.99]
4.2 Asia 1 436 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.13, 6.36]
4.3 Oceania 1 193 Risk Ratio (M-H, Fixed, 95% CI) 3.63 [1.04, 12.60]
5 P. vivax parasitaemia 4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 Mixed P. falciparum and
vivax infection at baseline
4 1608 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.73, 1.42]
5.2 P. vivax parasitaemia by
D28
1 473 Risk Ratio (M-H, Fixed, 95% CI) 0.05 [0.01, 0.36]
5.3 P. vivax parasitaemia by
D42
4 1442 Risk Ratio (M-H, Fixed, 95% CI) 0.32 [0.24, 0.43]
6 Gametocyte development (in
those negative at baseline)
4 1203 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.35, 2.59]
7 Anaemia 4 Mean Difference (IV, Fixed, 95% CI) Subtotals only
7.1 Mean haemoglobin (g/dl)
at baseline
4 1356 Mean Difference (IV, Fixed, 95% CI) -0.07 [-0.27, 0.13]
7.2 Mean haemoglobin (g/dl)
at day 28
1 134 Mean Difference (IV, Fixed, 95% CI) 0.36 [-0.03, 0.75]
7.3 Mean haemoglobin (g/dl)
at day 42
1 375 Mean Difference (IV, Fixed, 95% CI) 0.30 [-0.02, 0.62]
7.4 Mean change in
haemoglobin (g/dl) from
baseline to Day 42
2 835 Mean Difference (IV, Fixed, 95% CI) 0.26 [0.00, 0.51]
8 Serious adverse events (including
deaths)
5 2110 Risk Ratio (M-H, Fixed, 95% CI) 1.71 [0.66, 4.46]
9 Early vomiting 2 1147 Risk Ratio (M-H, Fixed, 95% CI) 1.38 [0.68, 2.78]
Comparison 3. Dihydroartemisinin-piperaquine vs Artesunate plus amodiaquine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total Failure (P. falciparum) Day
28 PCR unadjusted
2 679 Risk Ratio (M-H, Fixed, 95% CI) 0.53 [0.35, 0.81]
1.1 Africa 1 501 Risk Ratio (M-H, Fixed, 95% CI) 0.54 [0.34, 0.85]
1.2 Asia 1 178 Risk Ratio (M-H, Fixed, 95% CI) 0.50 [0.17, 1.42]
2 Total Failure (P. falciparum) Day
28 PCR adjusted
2 629 Risk Ratio (M-H, Fixed, 95% CI) 0.47 [0.23, 0.94]
2.1 Africa 1 458 Risk Ratio (M-H, Fixed, 95% CI) 0.59 [0.27, 1.27]
2.2 Asia 1 171 Risk Ratio (M-H, Fixed, 95% CI) 0.15 [0.02, 1.22]
Artemisinin-based combination therapy for treating uncomplicated malaria (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
111